Bacterial-platelet interactions: Virulence meets host defense

Future Microbiology

Volumn 5, Issue 3, 2010, Pages 471-506

  Yeaman, Michael R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adaptive immunity; Bacteria; Host defense; Immunobiology; Innate immunity; Kinocidin; Platelets; Virulence

Indexed keywords

ANTIINFECTIVE AGENT; CD40 LIGAND; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2; FIBRINOPEPTIDE A; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE 2; KINOCIDIN DERIVATIVE; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MYOSIN HEAVY CHAIN; NAFCILLIN; PLATELET DERIVED GROWTH FACTOR; PLATELET MICROBICIDAL PROTEIN; PROTEIN MD 2; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2X1 RECEPTOR; RANTES; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; THYMOSIN BETA4; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANCOMYCIN;

ADAPTIVE IMMUNITY; ANTIMICROBIAL ACTIVITY; AUTOIMMUNITY; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; CHEMOTAXIS; DEGRANULATION; DRUG EFFICACY; EFFECTOR CELL; ENDOTHELIUM CELL; ENERGY TRANSFER; GRAM NEGATIVE BACTERIUM; GRANULOCYTE; HOST CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TISSUE INJURY; WOUND HEALING;

BACTERIA; BACTERIAL ADHESION; BLOOD PLATELETS; HUMANS; VIRULENCE;

BACTERIA (MICROORGANISMS); PROKARYOTA;

EID: 77949406631     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.112     Document Type: Review

References (245)

1. Yeaman MR, Bayer AS: Platelets in Antimicrobial Host Defense. In: Platelets (Second Edition). Michelson A (Ed.). Academic Press, New York, NY, USA 727-755 (2006).
2. Klinger M, Jelkmann W: Role of blood platelets in infection and infammation. J. Interferon Cytokine Res. 22, 913-922 (2002).
3. Yeaman MR: The role of platelets in antimicrobial host defense. Clin. Infect. Dis. 25, 951-968 (1997).
4. Yeaman MR, Bayer AS: Antimicrobial peptides from platelets. Drug Resist. Updat. 2, 116-126 (1999).
5. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 238, 1-9 (2005).
6. Fitzgerald JR, Foster TJ, Cox D: The interaction of bacterial pathogens with platelets. Nat. Rev. Microbiol. 4, 445-457 (2006).
7. Ford I, Douglas CW: The role of platelets in infective endocarditis. Platelets 8, 285-294 (1997).
8. Fodor J: Die fahigkeit des blutes bakterien zu vernichten. Dtsch. Med. Wochenschr. 13, 745-747 (1887).
9. Gengou O: De l'origine de l'axenine de serums normaux. Ann. Inst. Pasteur (Paris) 15, 232-245 (1901).
10. Hirsch JG: Comparative bactericidal activities of blood serum and plasma serum. J. Exp. Med. 112, 15-22 (1960).
11. Tocantins LM: The mammalian blood platelet in health and disease. Medicine 17, 155-257 (1938).
12. Jago R, Jacox RF: Cellular source and character of a heat-stable bactericidal property associated with rabbit and rat platelets. J. Exp. Med. 113, 701-709 (1961).
13. Weksler BB: Induction of bactericidal activity in human platelets. Clin. Res. 19, 434-435 (1971).
14. Kahn RA, Flinton LJ: The relationship between platelets and bacteria. Blood 44, 715-721 (1974).
15. Czuprynski CJ, Balish E: Interaction of rat platelets with Listeria monocytogenes. Infect. Immun. 33, 103-108 (1981).
16. Miragliotta G, Lafata M, Jirilla E: Antibacterial activity mediated by human platelets. Agents Actions 25, 401-406 (1988).
17. Carroll SF, Martinez RJ: Antibacterial peptide from normal rabbit serum. I. Isolation from whole serum, activity, and microbiologic spectrum. Biochemistry 20, 5973-5981 (1981).
18. Carroll SF, Martinez RJ: Antibacterial peptide from normal rabbit serum. II. Compositional microanalysis. Biochemistry 20, 5981-5987 (1981).
19. Carroll SF, Martinez RJ: Antibacterial peptide from normal rabbit serum. III. Inhibition of microbial electron transport. Biochemistry 20, 5988-5994 (1981).
20. Myrvik QN: Serum bactericidins active against Gram-positive bacteria. Ann. NY Acad. Sci. 66, 391-400 (1956).
21. Jago R, Jacox RF: Cellular source and character of a heat-stable bactericidal property associated with rabbit and rat platelets. J. Exp. Med. 113, 701-709 (1961).
22. Myrvik QN, Leake ES: Studies on antibacterial factors in mammalian tissues and fuids. IV. Demonstration of two non-dialyzable components in the serum bactericidin system for Bacillus subtilis. J. Immunol. 84, 247-250 (1960).
23. Johnson FB, Donaldson DM: Purifcation of staphylocidal b-lysin from rabbit serum. J. Bacteriol. 96, 589-595 (1968).
24. Weksler BB, Nachman RL: Rabbit platelet bactericidal protein. J. Exp. Med. 134, 1114-1130 (1971).
25. Tew JG, Roberts RR, Donaldson DM. Release of b-lysin from platelets by thrombin and by a factor produced in heparinized blood. Infect. Immun. 9, 179-186 (1974).
26. Donaldson DM, Tew TG: b-lysin of platelet origin. Bacteriol. Rev. 41, 501-512 (1977).
27. Dankert J: Role of Platelets in Early Pathogenesis of Viridans Group Streptococcal endocarditis. PhD Dissertation, University of Groningen, The Netherlands.
28. Dankert J, van der Werff J, Zaat SAJ, Joldersma W, Klein D, Hess J: Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect. Immun. 63, 663-671 (1995).
29. Yeaman MR, Puentes SM, Norman DC, Bayer AS: Partial purifcation and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect. Immun. 60, 1202-1209 (1992).
30. Darveau RP, Blake J, Seachord CL et al.: Peptide related to the carboxy-terminus of human platelet factor IV with antibacterial activity. J. Clin. Invest. 90, 447-455 (1992).
31. Tang YQ, Yeaman MR, Selsted ME: Microbicidal and synergistic activities of human platelet factor-4 (hPF-4) and connective tissue activating peptide-3 (CTAP-3). Blood 86, 556a (1995).
32. Tang YQ, Yeaman MR, Selsted ME: Purifcation, characterization, and antimicrobial properties of peptides released from thrombin-induced human platelets. Blood 86, 910a (1995).
33. Tang YQ, Yeaman MR, Selsted ME: Antimicrobial proteins from human platelets. Infect. Immun. 70, 6524-6533 (2002).
34. Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME: Purifcation and in vitro activities of rabbit platelet microbicidal proteins. Infect. Immun. 65, 1023-1031 (1997).
35. Nachum R, Watson SW, Sullivan JD Jr, Siegel SE: Antimicrobial defense mechanisms in the horseshoe crab, Limulus polyphemus. preliminary observations with heat-derived extracts of Limulus amoebocyte lysate. J. Invert. Pathol. 32, 51-58 (1980).
36. Maluf NSR: The blood of arthropods. Quart. Rev. Biol. 14, 149-191 (1939).
37. Weksler BB: Infammation. Basic principles and clinical correlates. In: Platelets (Second Edition). Gallin JI, Goldstein IM, Snyderman R (Eds). Raven Press, Ltd., NY, USA 543-557 (1992).
38. Bancsi MJL, Thompson J, Bertina RM: Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infect. Immun. 62, 5669-5672 (1994).
39. Drake TA, Pang M: Staphylococcus aureus induces tissue factor expression in cultured human cardiac valve endothelium. J. Infect. Dis. 157, 749-756 (1988).
40. Drake TA, Rodgers GM, Sande MA: Tissue factor is a major stimulus for vegetation formation in enterococcal endocarditis in rabbits. J. Clin. Invest. 73, 1750-1753 (1984).
41. Colman RW: Receptors that activate platelets. Proc. Soc. Exp. Biol. Med. 197, 242-248 (1991).
42. Zarbock A, Polanowska-Grabowska RK, Ley K: Platlelet-neutrophil interactions Blood Rev. 21, 99-111 (2007).
43. White JG: Views of the platelet at rest and at work. Ann. NY Acad. Sci. 509, 156-176 (1987).
44. White JG, Sauk JJ. Microtubule coils in spread blood platelets. Blood 64, 470-478 (1984).
45. Price B, Flaumenhaft R: Platelet a-granules. basic biology and clinical correlates. Blood Rev. 23, 177-189 (2009).
46. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O: Evidence of Toll-like receptor molecules on human platelets. Immunol. Cell Biol. 83, 196-198 (2005).
47. Rex S, Beaulieu LM, Perlman DH et al.: Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and a-granule release. Thromb. Haemost. 102, 97-110 (2009).
48. Zhang G, Han J, Welch EJ et al.: Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J. Immunol. 182, 7997-8004 (2009).
49. Aslam R, Speck ER, Kim M et al.: Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-a production in vivo. Blood 107, 637-641 (2006).
50. Shiraki R, Inoue N, Kawasaki S et al.: Expression of Toll-like receptors on human platelets. Thromb. Res. 113, 379-385 (2004).
51. Scott T, Owens MD: Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF-kB pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E2. Mol. Immunol. 45, 1001-1008 (2008).
52. Martinson J, Bae J, Klingemann HG, Tam Y: Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC. Cytotherapy 6, 487-497 (2004).
53. Osler W: On certain problems in the physiology of the blood corpuscles. Med. News 48, 365-425 (1886).
54. Cheung AL, Fischetti VA: The role of fbrinogen in staphylococcal adherence to catheters in vitro. J. Infect. Dis. 161, 1177-1186 (1990).
55. Vinter DW, Burkel WE, Wakefeld TW et al.: Radioisotope-labeled platelet studies and infection of vascular grafts. J. Vasc. Surg. 6, 921-923 (1984).
56. Scheld WM, Valone JA, Sande MA: Bacterial adherence in the pathogenesis of infective endocarditis. interaction of dextran, platelets, and fbrin. J. Clin. Invest. 61, 1394-1404 (1978).
57. Durack DT: Experimental bacterial endocarditis. I V. Structure and evolution of very early lesions. J. Clin. Pathol. 45, 81-89 (1975).
58. Calderone RA, Rotondo MF, Sande MA: Candida albicans endocarditis: ultrastructural studies of vegetation formation. Infect. Immun. 20, 279-289 (1978).
59. Durack DT, Beeson PB, Petersdorf RG: Experimental bacterial endocarditis. III. Production of progress of the disease in rabbits. Br. J. Exp. Pathol. 54, 142-151 (1973).
60. Sullam PM, Drake TA, Sande MA: Pathogenesis of endocarditis. Am. J. Med. 78(Suppl. 6B)110-115 (1985).
61. Ferguson DJP, McColm AA, Savage TJ, Ryan DM, Acred P: A morphological study of experimental rabbit staphylococcal endocarditis and aortitis. I. Formation and effect of infected and uninfected vegetations on the aorta. Br. J. Exp. Pathol. 67, 667-678 (1986).
62. Scheld WM, Sande MA: Endocarditis and intravascular infections. In: Principles and Practice of Infectious Diseases (Fifth edition). Mandell GL, Bennet JE, Dolin R (Eds). Churchill Livingstone, NY, USA 740-782 (1995).
63. Clawson CC: Role of platelets in the pathogenesis of endocarditis. In: Infectious Endocarditis. American Heart Association Monograph no. 52. Kaplan EL, Taranta AV (Eds). American Heart Association, Dallas, TX, USA 24-27 (1977).
64. Roberts WC, Buchbinder NA: Right-sided valvular infective endocarditis: a clinicopathologic study of 12 necropsy patients. Am. J. Med. 53, 7-19 (1972).
65. Buchbinder NA, Roberts WC: Left-sided valvular infective endocarditis: a study of 45 necropsy patients. Am. J. Med. 53, 20-35 (1972).
66. Bureau MF, DeClerck F, Lefort J, Arreto CD, Vargaftig BB: Thromboxane A2 accounts for bronchoconstriction, but not for platelet sequestration and microvascular albumin exchanges induced by f-met-leu-phe in the guinea pig lung. J. Pharmacol. Exp. Ther. 260, 832-884 (1992).
67. Cosgrove LJ, de Apice AJ, Haddad A, Pedersen J, McKenzie IF: CR3 receptors on platelets and it role in the prostaglandin metabolic pathway. Immunol. Cell Biol. 65, 453-460 (1987).
68. Coyle AJ, Vargaftig BB: Animal models for investigating the allergic and infammatory properties of platelets. In: Immunopharmacology of Platelets. Joseph M (Ed.). Academic Press, Ltd., London, UK, 21-30 (1995).
69. Czapiga M, Gao JL, Kirk A, Lekstrom-Himes J: Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. Exp. Hematol. 33, 73-84 (2005).
70. Cognasse F, Hamzeh-Cognasse H, Lafarge S et al.: Toll-like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. Br. J. Haematol. 141, 84-91 (2008).
71. Aslam R, Speck ER, Kim M et al.: Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-a production in vivo. Blood 107, 637-641 (2006).
72. Pancré V, Monte D, Delanoye A, Capron A, Aurialt C: Interleukin-6, the main mediator of interaction between monocytes and platelets in killing of Schistosoma mansoni. Eur. Cytokine Net. 1, 15-19 (1990).
73. Blair P, Rex S, Vitseva O et al.: Stimulation of Toll-like receptor 2 in human platelets induces a thromboinfammatory response through activation of phosphoinositide 3-kinase. Circ. Res. 104, 346-354 (2009).
74. Elzey BD, Tian J, Jensen RJ et al.: Platelet-mediated modulation of adaptive immunity: a communication link between innate and adaptive immune compartments. Immunity 19, 9-19 (2003).
75. + T cells for enhanced germinal center formation: J. Leukoc. Biol. 78, 80-84 (2005).
76. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP: The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol. Res. (2009) (Epub ahead of print).
77. Miedzobrodzki J, Panz T, Ponka PM et al.: Platelets augment respiratory burst in neutrophils activated by selected species of Gram-positive or Gram-negative bacteria. Folia Histochem. Cytobiol. 46, 383-388 (2008).
78. Henn V, Slupsky JR, Gräfe M et al.: CD40 ligand on activated platelets triggers an infammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
79. Miyabe K, Sakamoto N, Wu YH, Mori N, Sakamoto H: Effects of platelet release products on neutrophilic phagocytosis and complement receptors. Throm. Res. 114, 29-36 (2004).
80. Clark SR, Ma AC, Tavener SA et al.: Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13, 463-469 (2007).
81. Kaushansky K: Historical review: megakaryopoiesis and thrombopoiesis. Blood 111, 981-986 (2008).
82. Italiano JE, Shivdasani RA: Megakaryocytes and beyond: the birth of platelets. J. Thromb. Haem. 1, 1174-1182 (2003).
83. White JG: Platelet morphology and function. In: Hematology. Williams WJ, Beutler E, Erslev AJ, Rundles RW (Eds.). McGraw-Hill, NY, USA 1023-1039 (1972).
84. Marcus AJ: Platelet function-part I. N. Engl. J. Med. 280, 1213-1220 (1969).
85. 14C-labelled serotonin. J. Clin. Invest. 40, 2134-2138 (1961).
86. Murphy EA, Robinson GA, Rowsell A: The pattern of platelet disappearance. Blood 30, 26-31 (1967).
87. Harker LA, Finch CA: Thrombokinetics in man. J. Clin. Invest. 48, 963-974 (1969).
88. Weyrich AS, Schwertz H, Kraiss LW, Zimmerman GA: Protein synthesis by platelets: historical and new perspectives. J. Thromb. Haemost. 7, 241-246 (2009).
89. Rosenfeld SI, Looney RJ, Leddy JP. Human platelet Fc receptor of immunoglobulin G. J. Clin. Invest. 76, 2317-2322 (1985).
90. Qian K, Xie F, Gibson AW, Edberg JC, Kimberly R P, Wu J: Functional expression of IgA receptor FcgRI on human platelets. J. Leukoc. Biol. 84, 1492-1500 (2008).
91. Joseph M, Aurialt C: A new function for platelets: IgE-dependent killing of schistosomes. Nature 303, 810-812 (1983).
92. Bout D, Joseph M, Ponet M: Rat resistance to schistosomiasis: platelet-mediated cytotoxicity induced by C-reactive protein. Science 231, 153-156 (1986).
93. Ochenhouse CF, Magowan C, Chulay JD. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to CD36 surface receptor in vitro. J. Clin. Invest. 84, 468-475 (1989).
94. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN: Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96, 4046-4054 (2000).
95. Jaff MS, McKenna D, McCann SR: Platelet phagocytosis: a probable mechanism of thrombocytopenia in Plasmodium falciparum infection. J. Clin. Pathol. 38, 1318-1319 (1985).
96. Movat HZ, Weiser WJ, Glynn MF, Mustard JF: Platelet phagocytosis and aggregation. J. Cell Biol. 27, 531-543 (1965).
97. Cognasse F, Hamzeh-Cognasse H, Berthet J et al.: Altered release of regulated upon activation, normal T-cell expressed and secreted protein from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides. AIDS 23, 2057-2059 (2009).
98. Azizi N, Li C, Shen AJ, Bayer AS, Yeaman MR: Staphylococcus aureus elicits release of platelet microbicidal proteins in vitro. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology. New Orleans, LA, USA, 19-25 May (1996) (Abstract 866, 36).
99. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL: Hyperproduction of a-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect. Immun. 65, 4652-4660 (1997).
100. MacFarlane DE, Mills DCB: The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood 46, 309-314 (1975).
101. Macfarlane DE, Walsh PN, Mills DC, Holmsen H, Day HJ: The role of thrombin in ADP-induced platelet aggregation and release: a critical evaluation. Br. J. Haematol. 30, 457-464 (1975).
102. Davies TA, Fine RE, Johnson RJ et al.: Non-age related differences in thrombin responses by platelets from male patients with advanced Alzheimer's disease. Biochem. Biophys. Res. Comm. 194, 537-543 (1993).
103. Ofosu FA, Dewar L, Craven SJ et al.: Coordinate activation of human platelet protease-activated receptor-1 and-4 in response to subnanomolar a-thrombin. J. Biol. Chem. 283, 26886-26893 (2008).
104. Yount NY, Yeaman MR: Multidimensional signatures in antimicrobial peptides. Proc. Natl Acad. Sci. USA 101, 7363-7368 (2004).
105. Yount NY, Yeaman MR: Structural congruence among membrane-active host defense polypeptides of diverse phylogeny. Biochim. Biophys. Acta 1758, 1373-1386 (2006).
106. Yeaman MR, Yount NY: Unifying themes in host defense effector polypeptides. Nat. Rev. Micro. 5, 727-740 (2007).
107. Yeaman MR, Waring AJ, Yount NY et al.: Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochem. Biophys. Acta. 1768, 609-619 (2007).
108. Kagan BL, Ganz T, Lehrer RI: Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology 87, 131-149 (1994).
109. Yeaman MR, Yount NY: Mechanisms of antimicrobial peptide action and resistance. Pharm. Rev. 55, 27-55 (2003).
110. Yount NY, Kupferwasser D, Spisni A et al.: Selective reciprocity in antimicrobial activity versus cytotoxicity of hBD-2 and crotamine. Proc. Natl Acad. Sci. USA 106, 14972-14977 (2009).
111. Yount NY, Waring AJ, Gank KD, Welch WH, Kupferwasser D, Yeaman MR: Structural correlates of antimicrobial activity in IL-8 and related human kinocidins. Biochem. Biophys. Acta. 1768, 598-608 (2007).
112. Yeaman MR: Antimicrobial peptides from platelets in defense against cardiovascular infections. In: Mammalian Host Defense Peptides. Devine DA, Hancock REW (Eds). Adv. Mol. Cell. Micro. Cambridge University Press 279-322 (2000).
113. Yeaman MR, Bayer AS: Staphylococcus aureus, platelets, and the heart. Curr. Infect. Dis. Reports 2, 281-298 (2004).
114. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM: Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167, 623-627 (2001).
115. Dürr M, Peschel A: Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect. Immun. 70, 6515-6517 (2002).
116. Yang D, Chen Q, Hoover DM et al.: Many chemokines including CCL20/MIP-3a display antimicrobial activity. J. Leukoc. Biol. 74, 448-455 (2003).
117. Yount NY, Andrés MT, Fierro JF, Yeaman MR: The g-core motif correlates with antimicrobial activity in Cys-containing kaliocin-1 originating from transferrins. Biochem. Biophys. Acta. 1768, 2862-2872 (2007).
118. Yount NY, Gank KD, Xiong YQ et al.: Platelet microbicidal protein-1: structural themes of a multifunctional antimicrobial peptide. Antimicrob. Agents Chemother. 48, 4395-4404 (2004).
119. Yeaman MR, Yount NY: Code among chaos: immunorelativity and the AEGIS model of antimicrobial peptides. Microbe 71, 21-27 (2005).
120. Anderson RC, Rehders M, Yu PL: Antimicrobial fragments of the pro-region of cathelicidins and other immune peptides. Biotechnol. Lett. 30, 813-818 (2008).
121. Krijgsveld J, Zaat SA, Meeldijk J et al.: Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J. Biol. Chem. 275, 20374-20381 (2000).
122. Maglott D, Ostell J, Pruitt KD, Tatiana T: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 1(33), D54-D58 (2005).
123. Sieprawska-Lupa M, Mydel P, Krawczyk K et al.: Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48, 4673-4679 (2004).
124. Yeaman MR, Yount NY, Edwards JE Jr, Brass EP: US7067621 (2006).
125. Schaffner A, King CC, Schaer D, Guiney DG: Induction and antimicrobial activity of platelet basic protein derivatives in human monocytes. J. Leukoc. Biol. 76, 1010-1018 (2004).
126. Bourbigot S, Dodd E, Horwood C et al.: Antimicrobial peptide RP-1 structure and interactions with anionic versus zwitterionic micelles. Biopolymers 91, 1-13 (2009).
127. Bourbigot S, Fardy L, Waring A, Yeaman MR, Booth V: Structure of chemokine-derived antimicrobial peptide IL-8a and interaction with detergent micelles and oriented lipid bilayers. Biochemistry 48, 10509-10521 (2009).
128. Zaiou M, Nizet V, Gallo RL: Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 120, 810-816 (2003).
129. Trier D, Gank K, Kupferwasser D et al.: Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced amplifcation and kinocidin release. Infect. Immun. 76, 5706-5713 (2008).
130. Niemann S, Spehr N, Van Aken H et al.: Soluble fbrin is the main mediator of Staphylococcus aureus adhesion to platelets. Circulation 110, 193-200 (2004).
131. Sharma A, Novak EK, Sojar HT, Swank RT, Kuramitsu HK, Genco RJ: Porphyromonas gingivalis platelet aggregation activity: outer membrane vesicles are potent activators of murine platelets. Oral Microbiol. Immunol. 15, 393-396 (2000).
132. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM: Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Invest. 101, 178-187 (1998).
133. Jones T, Yeaman MR, Sakoulas G et al.: Staphylococcus aureus clinical treatment failures with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry and reduced drug binding. Antimicrob. Agents Chemother. 52, 269-278 (2008).
134. Mukhopadhyay K, Whitmire W, Xiong YQ et al.: In vitro resistance of Staphylococcus aureus to tPMP-1 is associated with alterations in cytoplasmic membrane fuidity, and fatty acid and phospholipid composition and asymmetry. Microbiology 153, 1187-1197 (2007).
135. Weidenmaier C, Peschel A, Kempf VAJ, Lucindo N, Yeaman MR, Bayer AS: DltABCD-and MprF-mediated cell envelope modifcations of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73, 8033-8088 (2005).
136. Koo SP, Bayer AS, Sahl HG, Proctor RA, Yeaman MR: Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect. Immun. 64, 1070-1074 (1996).
137. Bayer AS, McNamara P, Yeaman MR et al: Transposon-disruption of the complex I NADH oxidoreductase gene (snoD) in Staphylococcus aureus is associated with reduced susceptibility to the microbicidal activity of thrombin-induced platelet microbicidal protein-1. J. Bacteriol. 188, 211-222 (2006).
138. Xiong YQ, Bayer AS, Yeaman MR: Inhibition of Staphylococcus aureus intracellular macromolecular synthesis by thrombin-induced platelet microbicidal proteins. J. Infect. Dis. 185, 348-356 (2002).
139. Xiong Y, Bayer AS, Elazegui L, Yeaman MR: A synthetic peptide modeled on a microbicidal domain of tPMP-1 recapitulates lethal anti-staphylococcal mechanisms of the native molecule. Antimicrob. Agents Chemother. 50, 3786-3792 (2006).
140. Yeaman MR, Gank KD, Bayer AS, Brass EP: Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46, 3883-3891 (2002).
141. Yeaman MR, Sullam PM, Dazin PF, Bayer AS: Characterization of Staphylococcus aureus-platelet binding by quantitative fow cytometric analysis. J. Infect. Dis. 166, 65-73 (1992).
142. Bayer AS, Sullam PM, Ramos M, Li C, Cheung AL, Yeaman MR: Staphylococcus aureus induces platelet aggregation via a fbrinogen-dependent mechanism which is independent of principal platelet glycoprotein IIb/IIIa fbrinogen binding domains. Infect. Immun. 63, 3634-3641 (1995).
143. Yeaman MR, Sullam PM, Dazin PF, Bayer AS: Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect. Immun. 62, 3416-3423 (1994).
144. Yeaman MR, Sullam PM, Dazin PF, Ghannoum MA, Edwards JE Jr, Bayer AS: Fluconazole and platelet microbicidal protein inhibit Candida adherence to platelets in vitro. Antimicrob. Agents Chemother. 38, 1460-1465 (1994).
145. Yeaman MR: Antimicrobial peptides: context drives strategy for enhancement of innate immune mechanisms. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology. Chicago, IL, USA, 13-17 September (2003) (Abstract 502, 43).
146. Mercier RC, Rybak MJ, Bayer AS, Yeaman MR: Infuence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis. Infect. Immun. 68, 4699-4705 (2000).
147. Mercier RC, Dietz RM, Mazzola JL, Bayer AS, Yeaman MR: Benefcial infuence of platelets on antibiotic effcacy in an in vitro model of Staphylococcus aureus endocarditis: Antimicrob. Agents Chemother. 48, 2551-2557 (2004).
148. Filler SG, Joshi M, Phan QT, Diamond RD, Edwards JE Jr, Yeaman MR: Platelets protect vascular endothelial cells from injury due to Candida albicans. Presented at: 39th ICAAC Meeting, American Society for Microbiolgy. San Francisco, CA, USA 26-29 September (1999) (Abstract 2163).
149. Lorenz R, Brauer M: Platelet factor-4 (PF4) in septicaemia. Infection 16, 273-276 (1988).
150. Mezzano S, Burgos ME, Ardiles L et al.: Glomerular localization of platelet factor 4 in streptococcal nephritis. Nephron 61, 58-63 (1992).
151. Ravid K, Beeler DL, Rabin MS, Ruley HE, Rosenberg RD: Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc. Natl Acad. Sci. USA 88, 1521-1525 (1990).
152. Rucinski B, Niewiarowski S, Strzyzewski M, Holt JC, Mayo KH: Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb. Haemost. 63, 493-498 (1991).
153. Dürr MC, Kristian SA, Otto M et al.: Neutrophil chemotaxis by pathogen-associated molecular patterns-formylated peptides are crucial but not the sole neutrophil attractants produced by Staphylococcus aureus. Cell Microbiol. 8, 207-217 (2006).
154. Kupferwasser LI, Yeaman MR, Shapiro S, Nast CC, Bayer AS: In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiologic, histologic, and echocardiographic analyses. Circulation 105, 746-752 (2002).
155. Wilson M, Blum R, Dandona P, Mousa S: Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and infammatory markers: a model of human diseases. Clin. Exp. Pharmacol. Physiol. 28, 376-380 (2001).
156. Yeaman MR, Kupferwasser D, Yount NY et al.: Effcacy of intravenous platelet kinocidin congener RP-1 in a murine model of Staphylococcus aureus (SA) bioflm infection. Presented at: 49th ICCAC, American Society for Microbiology. San Francisco, CA, USA October (2009) (Abstract B-1338, 49).
157. Kaushansky K: Molecular mechanisms of thromobopoietin signaling. J. Thromb. Haemost. 7, 235-238 (2009).
158. Lambert JR, Everington T, Linch DC, Gale RE: In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114, 3018-3023 (2009).
159. Nurden P, Nurden AT: Congenital disorders associated with platelet dysfunctions. Thromb. Haemost. 99, 253-263 (2008).
160. Krawczyk C, Penninger JM: Molecular controls of antigen receptor clustering and autoimmunity. Trends Cell Biol. 11, 212-220 (2001).
161. Althaus K, Greinacher A: MYH9-related platelet disorders. Semin. Thromb. Hemost. 35, 189-203 (2008).
162. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H: Inherited traits affecting platelet function. Blood Rev. 22, 155-172 (2009).
163. Hurford MT, Sebastiano C: Hermansky-pudlak syndrome: report of a case and review of the literature. Int. J. Clin. Exp. Pathol. 1, 550-554 (2008).
164. Sun H, Wang X, Degen JL, Ginsburg D: Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 113, 1358-1364 (2009).
165. Sullam PM, Frank U, Yeaman MR, Tauber MG, Bayer AS, Chambers HF: Effect of thrombocytopenia on the early course of streptococcal endocarditis. J. Infect. Dis. 168, 910-914 (1993).
166. Dankert J, Krijgsveld J, van Der Werff J, Joldersma W, Zaat SA: Platelet microbicidal activity is an important defense factor against viridans streptococcal endocarditis. J. Infect. Dis. 184, 597-605 (2001).
167. Feldman C, Kallenbach JM, Levy H, Thorburn JR, Hurwitz MD, Koornhof HJ: Comparision of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. Respiration 58, 265-270 (1991).
168. Chang FY, Singh N, Gayowski T et al.: Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation 69, 70-75 (2000).
169. Santolaya ME, Alvarez AM, Aviles CL et al.: Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin. Infect. Dis. 35, 678-683 (2002).
170. Yoshida T, Tsushima K, Tsuchiya A et al.: Risk factors for hospital-acquired bacteremia. Intern. Med. 44, 1157-1162 (2005).
171. Viscoli C, Bruzzi P, Castagnola E et al.: Factors associated with bacteraemia in febrile, granulocytopenic patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur. J. Cancer 30, 430-437 (1994).
172. Smith-Erichsen N: Serial determinations of platelets, leukocytes, and coagulation parameters in surgical septicemia. Scand. J. Clin. Lab. Invest. 178, 7-14 (1985).
173. Mavrommatis AC, Theodoridis T, Orfanidou A et al.: Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit. Care Med. 28, 451-457 (2000).
174. Bhat MA, Bhat JI, Kawoosa MS, Ahmad SM, Ali SW: Organism-specifc platelet response and factors affecting survival in thrombocytopenic very low birth weight babies with sepsis. J. Perinatol. 29, 702-708 (2009).
175. Elzey BD, Schmidt NW, Crist SA et al.: Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood 111, 3684-3691 (2008).
176. Iannacone M, Sitia G, Isogawa M et al.: Platelets prevent IFNa/binduced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc. Natl Acad. Sci. USA 105, 629-634 (2008).
177. Iannacone M, Sitia G, Isogawa M et al.: Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11, 1161-1169 (2005).
178. Clawson CC, White JG: Platelet interaction with bacteria: II. Fate of bacteria. Am. J. Pathol. 65, 381-398 (1971).
179. Clawson CC, White JG: Platelet interaction with bacteria: I. Reaction phases and effects of inhibitors. Am. J. Pathol. 65, 367-380 (1971).
180. Clawson CC:. Platelet interaction with bacteria. III. Ultrastructure. Am. J. Pathol. 70, 449-472 (1973).
181. Clawson CC, Rao GHR, White JG: Platelet interaction with bacteria: I V. Stimulation of the release reaction. Am. J. Pathol. 81, 411-420 (1975).
182. Forrester LJ, Campbell BJ, Berg JN, Barrett JT: Aggregation of platelets by Fusobacterium necrophorum. J. Clin. Microbiol. 22, 245-249 (1985).
183. Czuprynski CJ, Balish E: Interaction of rat platelets with Listeria monocytogenes. Infect. Immun. 33, 103-108 (1981).
184. Copley AL, Maupin B, Balea T: The agglutinant and adhesive behaviour of isolated human and rabbit platelets in contact with various strains of mycobacteria. Acta Tubercul. Scand. 37, 151-161 (1959).
185. Kessler CM, Nussbaum E, Tuazon CU: In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis. J. Lab. Clin. Med. 109, 647-652 (1987).
186. Timmons SA, Huzoor-Akbar, Grabarek J, Kloczewiak M, Hawiger J: Mechanism of human platelet activation by endotoxic glycolipid-bearing mutant Re595 of Salmonella minnesota. Blood 68, 1015-1023 (1986).
187. Mandell GL, Hook EW: The interaction of platelets, Salmonella, and mouse peritoneal macrophages. Proc. Soc. Exp. Biol. Med. 132, 757-759 (1969).
188. Simmonet M, Triadou P, Frehel C, Morel-Kopp M-CA, Kaplan CP: Human platelet aggregation by Yersinia pseudotuberculosis is mediated by invasin. Infect. Immun. 60, 366-373 (1992).
189. Ford I, Douglas C W, Preston SE, Lawless A, Hampton KK: Mechanisms of platelet aggregation by Streptococcus sanguis, a causative organism in infective endocarditis. Br. J. Hematol. 84, 85-100 (1993).
190. Kurpiewski GE, Forrester LJ, Campbell BJ, Barrett JT: Platelet aggregation by Streptococcus pyogenes. Infect. Immun. 39, 704-708 (1983).
191. Rasmussen M, Eden A, Bjorck L: SclA a novel collagen-like surface protein of Streptococcus pyogenes. Infect. Immun. 69, 6370-6377 (2000).
192. Pietrocola G, Schubert A, Visai L et al.: FbsA, a fbrinogen-binding protein from Streptococcus agalactiae, mediates platelet aggregation. Blood 105, 1052-1059 (2005).
193. Zimmerman TS, Spiegelberg HL: Pneumococcus-induced serotonin release from human platelets. J. Clin. Invest. 56, 828-834 (1975).
194. Zimmerman T, Spiegelberg H: Pneumococcus-induced serotonin release from human platelets: identifcation of the participating plasma/serum factor as immunoglobulin. J. Clin. Invest. 56, 828-834 (1975).
195. Sullam PM, Valone FH, Mills J: Mechanisms of platelet aggregation by viridans group streptococci. Infect. Immun. 55, 1743-1750 (1987).
196. Sullam PM, Jarvis GA, Valone FH: Role of immunoglobulin G in platelet aggregation by viridans group streptococci. Infect. Immun. 56, 2907-2911 (1988).
197. Fitzgerald JR, Loughman A, Keane F et al.: Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fbrinogen and fbronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgRIIa receptor. Mol. Microbiol. 59, 212-230 (2006).
198. Johnson CM, Bowie EJW: Pigs with von Willebrand disease may be resistant to experimental infective endocarditis. J. Lab. Clin. Med. 120, 553-558 (1992).
199. Herzberg MC, Brintzenhofe KL, Clawson CC: Aggregation of human platelets and adhesion of Streptococcus sanguis. Infect. Immun. 39, 1457-1469 (1983).
200. Herzberg MC, Gong K, MacFarlane GD et al.: Phenotypic characterization of Streptococcus sanguis virulence factors associated with bacterial endocarditis. Infect. Immun. 58, 515-522 (1990).
201. Gong K, Herzberg MC: Streptococcus sanguis expresses a 150-kilodalton two-domain adhesin: characterization of several independent adhesin epitopes. Infect. Immun. 65, 3815-3821 (1997).
202. Kerrigan SW, Jakubovics NS, Keane C et al.: Role of Streptococcus gordonii surface proteins SspA/SspB and Hsa in platelet function: Infect. Immun. 75, 5740-5747 (2007).
203. Bensing BA, Rubens CE, Sullam PM: Genetic loci of Streptococcus mitis that mediate binding to human platelets. Infect. Immun. 69, 1373-1380 (2001).
204. Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM: Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB: Mol. Microbiol. 64, 844-857 (2007).
205. Mitchell J, Sullam PM: Streptococcus mitis phage-encoded adhesins mediate attachment to a-2-8-linked sialic acid residues on platelet membrane gangliosides. Infect. Immun. 77, 3485-3490 (2009).
206. Xiong YQ, Bensing BA, Bayer AS, Chambers HF, Sullam PM: Role of the serine-rich surface glycoprotein GspB of Streptococcus gordonii in the pathogenesis of infective endocarditis. Microb. Pathog. 45, 297-301 (2008).
207. Takamatsu D, Bensing BA, Sullam PM: Four proteins encoded in the gspB-secY2A2 operon of Streptococcus gordonii mediate the intracellular glycosylation of the platelet-binding protein GspB. J. Bacteriol. 186, 7100-7111 (2004).
208. Sigurdsson AF, Gudmundsson S: The etiology of bacterial cellulitis as determined by fne-needle aspiration. Scand. J. Infect. Dis. 21(5), 537-542 (1989).
209. Diekema DJ, Pfaller MA, Schmitz FJ et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacifc region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32, S114-S132 (2001).
210. Carratala J, Roson B, Fernandez-Sabe N et al.: Factors associated with complications and mortality in adult patients hospitalized for infectious cellulites. Eur. J. Clin. Microbiol. Infect. Dis. 22(3), 151-157 (2003).
211. Brook I, Frazier EH: Clinical features and aerobic and anaerobic microbiological characteristics of cellulites. Arch. Surg. 130(7), 786-792 (1995).
212. Hoen B, Alla F, Selton-Suty C et al.: Changing profle of infective endocarditis: results of a 1-year survey in France. JAMA 288(1), 75-81 (2002).
213. Fowler VG Jr, Miro JM, Hoen B et al.: Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293(24), 3012-3021 (2005).
214. Miro JM, Anguera I, Cabell CH et al.: Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41(4), 507-514 (2005).
215. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis. 36(9), 1103-1110 (2003).
216. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
217. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel R P, Edmond MB: Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22, 686-691 (2003).
218. Mylotte JM, Kahler L, McCann C: Community-acquired bacteremia at a teaching versus a nonteaching hospital impact of acute severity of illness on 30-day mortality. Am. J. Infect. Control 29, 13-19 (2001).
219. Moreillon P, Que Y-A, Glauser MP: Staphylococcus aureus (including staphylococcal toxic shock). In: Principles and Practice of Infectious Diseases (6th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Elsevier, Philadelphia, PA, USA 2321-2351 (2005).
220. Siboo IR, Chambers HF, Sullam PM: Role of SraP, a serine-rich surface protein of Staphylococcus aureus in binding to human platelets. Infect. Immun. 73, 2273-2280 (2005).
221. Yeaman MR, Sullam PM, Dazin PF, Bayer AS: Characterization of Staphylococcus aureus-platelet binding by quantitative fow cytometric analysis. J. Infect. Dis. 166, 65-73 (1992).
222. Xiong YQ, Fowler VG, Yeaman MR, Remington FP, Kreiswirth BN, Bayer AS: Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J. Infect. Dis. 199, 201-208 (2009).
223. Cheung AL, Krishnan M, Jaffe EA, Fischetti VA: Fibrinogen acts as a bridging molecule in the adherence of Staphylococcus aureus to cultured human endothelial cells. J. Clin. Invest. 8 7, 2236-2245 (1991).
224. Clawson CC, White JG, Herzberg MC: Platelet interaction with bacteria: VI. Contrasting the role of fbrinogen and fbronectin. Am. J. Hematol. 9, 43-53 (1980).
225. Toy PTC, Lai LW, Drake TA, Sande MA: Effect of fbronectin on adherence of Staphylococcus aureus to fbrin thrombi in vitro. Infect. Immun. 48, 83-86 (1985).
226. Herrmann M, Suchard SJ, Boxer LA, Waldvogel FA, Lew PD: Thrombospondin binds to Staphylococcus aureus and promotes staphylococcal adherence to surfaces. Infect. Immun. 59, 271-288 (1991).
227. Loughman A, Fitzgerald JR, Brennan MP et al.: Roles for fbrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol. Microbiol. 57, 804-818 (2002).
228. Youssefan T, Drouin A, Masse JM, Guichard J, Cramer EM: Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specifc subcellular compartment and is enhanced by platelet activation. Blood 99, 4021-4029 (2005).
229. Hawiger J, Streackley S, Hammond D et al.: Staphylococcal-induced human platelet injury mediated by protein A and immunoglobulin G Fc receptor. J. Clin. Invest. 64, 931-937 (1979).
230. Brennan M, Loughman A, Devocelle M et al.: Elucidating the role of Staphylococcus epidermidis serine-aspartate repeat protein G (SdrG) in platelet activation. J. Thromb. Haemost. 7, 1364-1372 (2009).
231. Bayer AS, Ramos MD, Menzies BE, Yeaman MR, Shen AJ, Cheung AL: Hyperproduction of a-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect. Immun. 65, 4652-4660 (1997).
232. Shepel M, Boyd J, Luider J, Gibb AP: Interaction of Yersinia enterocolitica and Y. pseudotuberculosis with platelets. J. Med. Microbiol. 50, 1030-1038 (2001).
233. Salden HJ, Bas BM: Endotoxin binding to platelets in blood from patients with a sepsis syndrome. Clin. Chem. 40, 1575-1579 (1994).
234. Coutinho IR, Berk RS, Mammen E: Platelet aggregation by a phospholipase C from Pseudomonas aeruginosa. Thromb. Res. 51, 495-505 (1988).
235. Machado GB, de Assis MC, Leão R et al.: ExoU-induced vascular hyperpermeability and platelet activation in the course of experimental Pseudomonas aeruginosa pneumosepsis. Shock (2009) (Epub ahead of print).
236. Piguet PF, Vesin C, Ryser JE, Senaldi G, Grau GF, Tachini-Cottier F: An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a-and CD54a-dependent interaction with endothelium. Infect. Immum. 61, 82-87 (1993).
237. Smith CW: Leukocyte-endothelial cell interaction. Sem. Hematol. 30, 45-55 (1993).
238. Brennan RO, Durack DT: Therapeutic signifcance of penicillin tolerance in experimental streptococcal endocarditis: Antimicrob. Agents Chemother. 23, 273-277 (1983).
239. Maisch PA, Calderone RA: Adherence of Candida albicans to a fbrin-platelet matrix formed in vitro. Infect. Immun. 27, 650-656 (1980).
240. Klotz SA, Harrison JL, Misra RP: Aggregated platelets enhance adherence of Candida yeasts to endothelium. J. Infect. Dis. 160, 669-677 (1989).
241. Yeaman MR, Norman DC, Bayer AS: Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence or aggregation in vitro. Infect. Immun. 60, 2368-2374 (1992).
242. Rober A, Marot-Leblond: Molecular basis of the interaction between Candida albicans, fbrinogen, and platelets. J. Mycol. Med. 2, 19-25 (1992).
243. Nicolau DP, Freeman CD, Nightingale CH et al.: Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect. Immun. 61, 1593-1595 (1993).
244. Nguyen T, Ghebrehiwet B, Peerschke EI: Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect. Immun. 68, 2061-2068 (2000).
245. Ohba M, Shibazaki M, Sasano T, Inoue M, Takada H, Endo Y: Platelet responses and anaphylaxis-like shock induced in mice by intravenous injection of whole cells of oral streptococci. Oral. Microbiol. Immunol. 19, 26-30 (2004).